Science-based nutraceutical company LifeVantage Corp. today announced the publication of a peer-reviewed study involving Protandim®, the company’s clinically proven therapy for oxidative stress.
Protandim is an indirect antioxidant therapy providing substantial benefits for healthy aging by stimulating the body’s production of its natural antioxidant enzymes.
The study, titled “The Chemopreventive Effects of Protandim: Modulation of p53 Mitochondrial Translocation and Apoptosis during Skin Carcinogenesis,” demonstrates Protandim’s ability to reduce the incidence and number of skin cancers in mice.
The report was published in the scientific journal PLoS ONE, conducted by researchers at Louisiana State University who examined the biochemical mechanisms that underlie Protandim’s efficacy in a two-stage model. The first stage initiation involves DNA mutation, while the second stage, the promotion stage, induces existing tumor cells to proliferate.
According to the report, the study results suggest Protandim’s ability to signal the cell to suppress p53, which decreases levels of Bax, a protein that causes programmed cell death or apoptosis. When combined with increasing levels of super oxide dismutase, this may play an important role in the tumor suppressive activity of Protandim in this mouse model.
In an earlier human trial, Protandim increased antioxidant enzyme production, thereby eliminating the age-dependent increase in the most widely used marker of oxidative stress.
The study was independently funded by the Louisiana State University Health Sciences Center at Shreveport.
For more information visit www.LifeVantage.com